A Study With SAGE-547 for Super-Refractory Status Epilepticus

Summary

This is a randomized, double-blind, placebo-controlled trial, designed to evaluate the efficacy and safety of SAGE-547 administered as a continuous intravenous infusion to subjects in Super-Refractory Status Epilepticus (SRSE).

Timeline

Start

2015-06

Primary completion

2017-07-18

Completion

2017-08-11

Drugs

Indications